REGENERON PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
REGENERON PHARMACEUTICALS, INC. (REGN) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $13.90 billion as of 2025-09-30, per its 10-Q filed 2025-10-28.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2025-10-28
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $13.90B.
- 2025-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $13.08B.
- 2025-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $11.83B.
- 2024-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $12.18B.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months as first filed |
|---|---|---|
| 2025-09-30 | $13.90B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $13.08B 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $11.83B 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $12.18B 10-Q · filed 2025-10-28 | |
| 2024-09-30 | $12.34B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $10.92B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $10.71B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $7.85B 10-K · filed 2025-02-05 | |
| 2023-09-30 | $5.41B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $4.34B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $1.22B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $3.30B 10-K · filed 2024-02-05 | |
| 2022-09-30 | $6.46B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $9.13B 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $8.67B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $6.52B 10-K · filed 2023-02-06 | |
| 2021-09-30 | $2.93B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $1.31B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $1.46B 10-Q · filed 2021-05-06 | |
| 2020-09-30 | $606.00M 10-Q · filed 2020-11-05 | |
| 2020-03-31 | $2.04B 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $274.50M 10-Q · filed 2020-11-05 | |
| 2019-09-30 | $313.30M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $312.80M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $517.30M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $1.48B 10-K · filed 2020-02-07 | |
| 2018-09-30 | $1.43B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $1.64B 10-Q · filed 2018-08-02 | |
| 2017-12-31 | $1.04B 10-K · filed 2019-02-07 | $1.04B 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |